Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 1,246 | 3,225 | 2,386 | 1,915 | 2,998 |
| Cost of Goods | 169 | 127 | 119 | 102 | 235 |
| Gross Profit | 1,077 | 3,098 | 2,267 | 1,813 | 2,763 |
| Operating Expenses | 7,951 | 8,249 | 9,028 | 8,554 | 8,249 |
| Operating Income | -6,705 | -5,024 | -6,642 | -6,639 | -5,251 |
| Other Income | -453 | -179 | 435 | 277 | -324 |
| Pre-tax Income | -7,158 | -5,203 | -6,207 | -6,362 | -5,575 |
| Income Tax | 0 | N/A | -1,803 | N/A | 541 |
| Net Income Continuous | -7,158 | -5,203 | -4,404 | -6,362 | -6,116 |
| Minority Interests | -48 | 26 | -32 | -8 | -47 |
| Net Income | $-7,110 | $-5,229 | $-4,372 | $-6,354 | $-6,069 |
| EPS Basic Total Ops | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 |
| EPS Basic Continuous Ops | -0.04 | -0.03 | -0.03 | -0.04 | -0.04 |
| EPS Diluted Total Ops | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 |
| EPS Diluted Continuous Ops | -0.04 | -0.03 | -0.03 | -0.04 | -0.04 |
| EBITDA(a) | $-6,524 | $-4,773 | $-6,471 | $-6,477 | $-5,075 |